ClinicalTrials.gg
Not yet recruitingNCT07764627Updated Aug 17, 2026

Study of SG301 for Renal AMR After Transplantation

A Phase 2 interventional study of SG301 Injection in Antibody Mediated Rejection, sponsored by Hangzhou Sumgen Biotech Co., Ltd.. Not yet recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Hangzhou Sumgen Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of SG301 injection in patients with antibody-mediated rejection (AMR) after renal transplantation.

Read the detailed description

This study is a prospective, single arm, open label Phase II clinical trial enrolling patients with antibody mediated rejection (AMR) after renal transplantation. It aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SG301 injection in this patient population, and to obtain preliminary efficacy signals through renal biopsy at Week 25 (assessed per Banff 2022 criteria) and changes in donor specific antibody (DSA) levels, among other measures.

02

Conditions studied

  • Antibody Mediated Rejection
03

In context

Lead sponsor

Hangzhou Sumgen Biotech Co., Ltd. is the lead sponsor of 12 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the written form;
  2. Age ≥18 and ≤75 years;
  3. Expected survival ≥3 months;
  4. ≥180 days after renal transplantation, with stable graft function (from living or deceased donor);
  5. -confirmed active or chronic active AMR (with or without peritubular capillary C4d deposition), per Banff 2022 classification;
  6. DSA: within 6 months prior to first dose, donor specific antibodies (DSA) specific to HLA class I and/or II antigens (pre existing and/or de novo) confirmed by local laboratory and meeting the local laboratory's positive definition;
  7. Estimated (eGFR) ≥20 mL/min/1.73 m² at screening (CKD EPI formula);
  8. Recovery from adverse events due to prior treatment to ≤ Grade 1 ( v6.0), except for toxicities such as alopecia that are judged by the investigator to have no safety risk and not to violate other inclusion/exclusion criteria;
  9. Female participants of or male participants whose partners are of childbearing potential must remain abstinent or use reliable measures during the study treatment period and for at least 6 months after the last dose of SG301. Male participants must refrain from sperm donation during the study and for at least 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant T cell-mediated rejection (TCMR);
  2. New-onset or recurrent severe thrombotic microangiopathy; polyomavirus nephropathy; new-onset or recurrent glomerulonephritis;
  3. Prior treatment with other anti-CD38 monoclonal antibodies;
  4. Use of other monoclonal/polyclonal antibody agents within 3 months prior to the first dose of study drug;
  5. Latent or active tuberculosis, or active viral (, , , CMV), bacterial, or fungal infection requiring systemic therapy, or other active infections requiring systemic treatment;
  6. Active that makes the patient unsuitable for immunosuppressive therapy;
  7. Presence of serious medical or psychiatric illness that may interfere with the smooth conduct of the study;
  8. Prior multi-organ transplantation (including en bloc or dual kidney transplantation);
  9. Acute, rapid decline in renal function such that, in the investigator's judgement, the participant is likely to require renal replacement therapy within the subsequent 30 days;
  10. Receipt of any of the following treatments for AMR or TCMR within 3 months prior to the first dose of study drug (with the exception of ):

    1. Intravenous or subcutaneous immunoglobulin (IVIg/SCIg), plasma exchange, or immunoadsorption (antibody-depleting therapies);
    2. Complement system inhibitors (e.g., eculizumab);
    3. Proteasome inhibitors (e.g., bortezomib);
    4. Tocilizumab;
    5. Other drugs within 3 months or 5 half-lives (whichever is longer) prior to start of study treatment;
  11. Female participants who are pregnant or breastfeeding;
  12. Other conditions that, in the investigator's judgement, would make the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    SG301 Injection

    This study uses a 28-day treatment cycle. In Cycle 1, SG301 is administered once weekly for 4 doses (QW×4); starting from Cycle 2, it is administered once per cycle (i.e., once every 4 weeks) for 12 doses (Q4W×12), totaling 16 doses.

    Drug: SG301 Injection

Interventions

  • Dosage form: solution for infusion; Route of administration: intravenous; Frequency: weekly intervals (QW) for 4 weeks, then every 4 weeks (Q4W) for 48 weeks.

06

What researchers measure

Primary outcomes

  1. safety events

    Number of participants experiencing study-specific safety events or meeting treatment stopping criteriaNumber of participants experiencing study-specific safety events or meeting treatment stopping criteria

    Time frame: Up to Week 52

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 14, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764627
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Jing Yang
Contact
yangjing@sumgenbio.com
86-15210969106

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sanritatug

Start the discussion